US senator alleges FDA tried to prevent Adderall XR withdrawal in Canada.
作者信息
Eggertson Laura
出版信息
CMAJ. 2005 Mar 29;172(7):865. doi: 10.1503/cmaj.050266. Epub 2005 Mar 9.
Abstract
摘要
相似文献
1
US senator alleges FDA tried to prevent Adderall XR withdrawal in Canada.
CMAJ. 2005 Mar 29;172(7):865. doi: 10.1503/cmaj.050266. Epub 2005 Mar 9.
2
Adderall XR: long acting stimulant for single daily dosing.
Expert Rev Neurother. 2004 Nov;4(6):927-34. doi: 10.1586/14737175.4.6.927.
3
Adderall and other drugs for attention-deficit/hyperactivity disorder.
Med Lett Drugs Ther. 1994 Nov 25;36(936):109-10.
4
Adderall and seizures.
J Am Acad Child Adolesc Psychiatry. 2002 Apr;41(4):365. doi: 10.1097/00004583-200204000-00005.
5
An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Ann Pharmacother. 2009 Jun;43(6):1084-95. doi: 10.1345/aph.1L523. Epub 2009 May 26.
6
ADHD drugs and cardiovascular risk.
N Engl J Med. 2006 Apr 6;354(14):1445-8. doi: 10.1056/NEJMp068049. Epub 2006 Mar 20.
7
Adderall, the atypicals, and weight gain.
J Am Acad Child Adolesc Psychiatry. 2001 Jun;40(6):620. doi: 10.1097/00004583-200106000-00004.
8
Questions about Adderall XR.
CMAJ. 2006 Apr 25;174(9):1303-4. doi: 10.1503/cmaj.1060004.
9
Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD.
J Atten Disord. 2007 Jul;11(1):74-82. doi: 10.1177/1087054706292196.
10
Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.
Mt Sinai J Med. 2009 Apr;76(2):198-203. doi: 10.1002/msj.20096.
引用本文的文献
1
The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial.
Orphanet J Rare Dis. 2014 Sep 10;9:142. doi: 10.1186/s13023-014-0142-4.
Zotero 插件